Year |
Citation |
Score |
2020 |
Seth S, Huo L, Vasaikar S, Rauch G, Lim B, White J, Adrada B, Piwnica-Worms H, Ueno NT, Thompson AM, Mittendorf E, Tripathy D, Litton JK, Symmans WF, Draetta G, ... ... Chang J, et al. Abstract P2-16-08: Longitudinal response and selection under neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443) Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P2-16-08 |
0.313 |
|
2020 |
Echeverria GV, Xu M, Shao J, Zhang X, Jeter-Jones S, Zhou X, Moulder SL, Marszalek JR, Heffernan TP, Symmans FW, Chang JT, Piwnica-Worms H. Abstract GS4-02: Investigating genomic and phenotypic evolution of triple negative breast cancer chemoresistance and metastasis in patient-derived xenografts Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs4-02 |
0.348 |
|
2020 |
Seth S, Huo L, Rauch GM, Adrada B, Piwnica-Worms H, Lim B, Thompson AM, Mittendorf EA, Heffernan T, Litton JK, Symmans WF, Draetta GF, Futreal AP, Chang JT, Moulder SL. Abstract 1497: Longitudinal response and selection under neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized trial (ARTEMIS; NCT02276443) Tumor Biology. DOI: 10.1158/1538-7445.Am2020-1497 |
0.302 |
|
2019 |
Griffiths JI, Cohen AL, Jones V, Salgia R, Chang JT, Bild AH. Opportunities for improving cancer treatment using systems biology. Current Opinion in Systems Biology. 17: 41-50. PMID 32518857 DOI: 10.1016/J.Coisb.2019.10.018 |
0.337 |
|
2019 |
Ramirez-Peña E, Arnold J, Shivakumar V, Joseph R, Vidhya Vijay G, den Hollander P, Bhangre N, Allegakoen P, Prasad R, Conley Z, Matés JM, Márquez J, Chang JT, Vasaikar S, Soundararajan R, et al. The Epithelial to Mesenchymal Transition Promotes Glutamine Independence by Suppressing Expression. Cancers. 11. PMID 31652551 DOI: 10.3390/Cancers11101610 |
0.369 |
|
2019 |
Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, Lim B, Parra ER, et al. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers. 11. PMID 31137625 DOI: 10.3390/Cancers11050714 |
0.366 |
|
2019 |
Echeverria GV, Ge Z, Seth S, Zhang X, Jeter-Jones S, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Sun Y, Qiu H, Chang Q, Bristow C, Carugo A, ... ... Chang JT, et al. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Science Translational Medicine. 11. PMID 30996079 DOI: 10.1126/Scitranslmed.Aav0936 |
0.326 |
|
2019 |
Vijay GV, Zhao N, Den Hollander P, Toneff MJ, Joseph R, Pietila M, Taube JH, Sarkar TR, Ramirez-Pena E, Werden SJ, Shariati M, Gao R, Sobieski M, Stephan CC, Sphyris N, ... ... Chang JT, et al. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer. Breast Cancer Research : Bcr. 21: 37. PMID 30845991 DOI: 10.1186/S13058-019-1125-0 |
0.355 |
|
2019 |
Seth S, Huo L, Rauch GM, Adrada BE, Piwnica-Worms H, Thompson AM, Mittendorf EA, Litton JK, Symmans WF, Draetta GF, Futreal A, Moulder SL, Chang J. Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443). Journal of Clinical Oncology. 37: 586-586. DOI: 10.1200/Jco.2019.37.15_Suppl.586 |
0.3 |
|
2019 |
Seth S, Huo L, Rauch G, Lau R, Gilcrease M, Adrada B, Piwnica-Worms H, Symmans W, Draetta G, Futreal A, Moulder S, Chang J. Abstract P3-07-01: Towards a therapeutically relevant subtyping scheme for triple-negative breast cancer (TNBC), profiling results from A Randomized, TNBC Enrolling trial to confirm Molecular profiling Improves Survival (ARTEMIS) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P3-07-01 |
0.38 |
|
2019 |
Echeverria G, Ge Z, Seth S, Jeter-Jones S, Zhang X, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Lau R, Shao J, Sun Y, Bristow C, Carugo A, ... ... Chang J, et al. Abstract GS5-05: Resistance to neoadjuvant chemotherapy in triple negative breast cancer mediated by a reversible drug-tolerant state Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Gs5-05 |
0.342 |
|
2019 |
Echeverria GV, Ge Z, Seth S, Powell E, Zhang X, Jeter-Jones S, Zhou X, Jiang Y, McCoy A, Cai S, Tu Y, Peoples M, Sun Y, Qiu H, Bristow C, ... ... Chang JT, et al. Abstract 2901: Clonal dynamics and phenotypic evolution during chemoresistance and metastasis revealed by patient-derived xenograft models of triple negative breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2901 |
0.322 |
|
2019 |
Joseph R, Soundararajan R, Vasaikar S, Yang F, Isgandarova S, Tian L, Haemmerle M, Mino B, Zhou T, Raja GV, Pena ER, Hollander PD, Bhangre N, Shin C, Martinez M, ... ... Chang J, et al. Abstract 3761: Regulation of metastasis by CD8 T lymphocytes Cancer Research. 79: 3761-3761. DOI: 10.1158/1538-7445.Am2019-3761 |
0.332 |
|
2018 |
Echeverria GV, Powell E, Seth S, Ge Z, Carugo A, Bristow C, Peoples M, Robinson F, Qiu H, Shao J, Jeter-Jones SL, Zhang X, Ramamoorthy V, Cai S, Wu W, ... ... Chang JT, et al. High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. Nature Communications. 9: 5079. PMID 30498242 DOI: 10.1038/S41467-018-07406-4 |
0.328 |
|
2018 |
Zuo Y, Ulu A, Chang JT, Frost JA. Contributions of the RhoA guanine nucleotide exchange factor Net1 to polyoma middle T antigen-mediated mammary gland tumorigenesis and metastasis. Breast Cancer Research : Bcr. 20: 41. PMID 29769144 DOI: 10.1186/S13058-018-0966-2 |
0.324 |
|
2018 |
Echeverria G, Cai S, Tu Y, McCoy A, Lau R, Redwood A, Rauch G, Adrada B, Candelaria R, Santiago L, Thompson A, Litton J, Moulder S, Symmans F, Chang J, et al. Abstract P5-05-01: A molecularly annotated collection of breast cancer patient-derived xenograft models aligned with ongoing clinical trials built from fine needle aspiration samples throughout neoadjuvant treatment Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P5-05-01 |
0.354 |
|
2018 |
Echeverria G, Seth S, Ge Z, Sun Y, DiFrancesco E, Lau R, Marszalek J, Moulder S, Symmans F, Heffernan T, Chang J, Piwnica-Worms H. Abstract P4-03-02: Characterizing and targeting chemoresistant subclones in patient-derived xenograft models of triple negative breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P4-03-02 |
0.321 |
|
2018 |
Soundararajan R, Paranjape A, Joseph R, Bhangre N, Aparicio A, Maity S, Logothetis C, Chang J, Mani S. Abstract A065: Modulating a cancer stem cell-specific signaling pathway to reverse the course of neuroendocrine prostate cancer Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A065 |
0.331 |
|
2017 |
Wang Z, Zhang F, He J, Wu P, Tay LWR, Cai M, Nian W, Weng Y, Qin L, Chang JT, McIntire LB, Di Paolo G, Xu J, Peng J, Du G. Binding of PLD2-Generated Phosphatidic Acid to KIF5B Promotes MT1-MMP Surface Trafficking and Lung Metastasis of Mouse Breast Cancer Cells. Developmental Cell. PMID 29033361 DOI: 10.1016/J.Devcel.2017.09.012 |
0.328 |
|
2017 |
Taube JH, Sphyris N, Johnson KS, Reisenauer KN, Nesbit TA, Joseph R, Vijay GV, Sarkar TR, Bhangre NA, Song JJ, Chang JT, Lee MG, Soundararajan R, Mani SA. The H3K27me3-demethylase KDM6A is suppressed in breast cancer stem-like cells, and enables the resolution of bivalency during the mesenchymal-epithelial transition. Oncotarget. 8: 65548-65565. PMID 29029452 DOI: 10.18632/Oncotarget.19214 |
0.357 |
|
2017 |
McQuerry JA, Chang JT, Bowtell DDL, Cohen A, Bild AH. Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes. Journal of Molecular Medicine (Berlin, Germany). PMID 28871446 DOI: 10.1007/S00109-017-1587-4 |
0.33 |
|
2017 |
Tang X, Ding CK, Wu J, Sjol J, Wardell S, Spasojevic I, George D, McDonnell DP, Hsu DS, Chang JT, Chi JT. Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling. Oncogene. PMID 28604749 DOI: 10.1038/Onc.2017.192 |
0.308 |
|
2017 |
He J, Zhang F, Tay LW, Boroda S, Nian W, Levental KR, Levental I, Harris TE, Chang JT, Du G. Lipin-1 regulation of phospholipid synthesis maintains endoplasmic reticulum homeostasis and is critical for triple-negative breast cancer cell survival. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 28347999 DOI: 10.1096/Fj.201601353R |
0.351 |
|
2017 |
Baez Vallecillo L, Chang JT, Chen K, Moss TJ, Shaw KR, Meric-Bernstam F, Eterovic AK, Mills GB, Mani S, Li X(, Gilcrease M, Moulder SL. Whole exome sequencing of metaplastic breast cancer (MpBC): Effect of mutation status on survival. Journal of Clinical Oncology. 35: 1090-1090. DOI: 10.1200/Jco.2017.35.15_Suppl.1090 |
0.302 |
|
2017 |
Echeverria G, Chang J, Cai S, Tu Y, McCoy A, Lau R, Redwood A, Kaffiabasabadi S, Rauch G, Adrada B, Jennifer L, Moulder S, Symmans W, Piwnica-Worms H. Abstract P4-06-03: An annotated collection of pre- and post-therapy breast cancer patient-derived xenograft models built from fine needle aspiration samples aligned with ongoing clinical trials documenting response to treatment Cancer Research. DOI: 10.1158/1538-7445.Sabcs16-P4-06-03 |
0.315 |
|
2016 |
Tisza MJ, Zhao W, Fuentes JS, Prijic S, Chen X, Levental I, Chang JT. Motility and stem cell properties induced by the epithelial-mesenchymal transition require destabilization of lipid rafts. Oncotarget. PMID 27303921 DOI: 10.18632/Oncotarget.9928 |
0.313 |
|
2016 |
Werden SJ, Sphyris N, Sarkar TR, Paranjape AN, LaBaff AM, Taube JH, Hollier BG, Ramirez-Peña EQ, Soundararajan R, den Hollander P, Powell E, Echeverria GV, Miura N, Chang JT, Piwnica-Worms H, et al. Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth. Oncogene. PMID 27292262 DOI: 10.1038/Onc.2016.203 |
0.346 |
|
2016 |
Zhao W, Prijic S, Urban BC, Tisza MJ, Zuo Y, Li L, Tan Z, Chen X, Mani SA, Chang JT. Candidate anti-metastasis drugs suppress the metastatic capacity of breast cancer cells by reducing membrane fluidity. Cancer Research. PMID 26825169 DOI: 10.1158/0008-5472.Can-15-1970 |
0.373 |
|
2016 |
Paranjape AN, Soundararajan R, Werden SJ, Joseph R, Taube JH, Liu H, Rodriguez-Canales J, Sphyris N, Wistuba I, Miura N, Dhillon J, Mahajan N, Mahajan K, Chang JT, Ittmann M, et al. Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. Oncogene. PMID 26804168 DOI: 10.1038/Onc.2015.498 |
0.302 |
|
2016 |
Echeverria G, Seth S, Moulder S, Symmans W, Chang J, Cai S, Heffernan T, Piwnica-Worms H. Abstract P3-06-04: Investigating clonal dynamics in triple negative breast cancer chemoresistance Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-06-04 |
0.363 |
|
2016 |
Ebelt ND, Taveres CDJ, Xie X, Naguib YW, Jose J, Ruwona TB, Devkota AK, Park J, Kaoud TS, Anslyn EV, Chang JT, Cui Z, Bartholomeusz C, Dalby KN. Abstract 3774: KD06 is a novel anti-cancer drug that causes cell death in triple-negative breast cancer cell lines and tumor xenografts Cancer Research. 76: 3774-3774. DOI: 10.1158/1538-7445.Am2016-3774 |
0.354 |
|
2016 |
Echeverria GV, Seth S, Cai S, Moulder S, Symmans WF, Heffernan TP, Chang J, Piwnica-Worms H. Abstract 2406: Identifying and targeting chemoresistant subclones in triple negative breast cancer Cancer Research. 76: 2406-2406. DOI: 10.1158/1538-7445.Am2016-2406 |
0.357 |
|
2015 |
Soundararajan R, Paranjape AN, Barsan V, Chang JT, Mani SA. A novel embryonic plasticity gene signature that predicts metastatic competence and clinical outcome. Scientific Reports. 5: 11766. PMID 26123483 DOI: 10.1038/Srep11766 |
0.351 |
|
2015 |
Sarkar TR, Battula VL, Werden SJ, Vijay GV, Ramirez-Peña EQ, Taube JH, Chang JT, Miura N, Porter W, Sphyris N, Andreeff M, Mani SA. GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene. 34: 2958-67. PMID 25109336 DOI: 10.1038/Onc.2014.245 |
0.369 |
|
2015 |
Hong B, Li H, Zhang M, Xu J, Lu Y, Zheng Y, Qian J, Chang JT, Yang J, Yi Q. p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion. International Journal of Cancer. Journal International Du Cancer. 136: 34-43. PMID 24806617 DOI: 10.1002/Ijc.28958 |
0.352 |
|
2015 |
Zhao W, Sara P, Urban B, Tisza M, Mani SA, Chang JT. Abstract B2-10: Systems biology reveals role of cholesterol homeostasis in breast cancer metastasis Cancer Research. 75. DOI: 10.1158/1538-7445.Compsysbio-B2-10 |
0.367 |
|
2015 |
Paranjape AN, Soundararajan R, Werden SJ, Joseph R, Taube JH, Bhangre N, Liu H, Rodriguez-Canales J, Wistuba II, Chang JT, Tang DG, Mahajan N, Mahajan K, Miura N, Mani SA. Abstract 4065: Delineating the role of epithelial-mesenchymal transition in the generation and maintenance of prostate cancer stem cells Cancer Research. 75: 4065-4065. DOI: 10.1158/1538-7445.Am2015-4065 |
0.328 |
|
2015 |
Li L, Chang J, Du G, Amato R, Li W. Abstract 1433: CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression Cancer Research. 75: 1433-1433. DOI: 10.1158/1538-7445.Am2015-1433 |
0.357 |
|
2014 |
Gong X, Yi J, Carmon KS, Crumbley CA, Xiong W, Thomas A, Fan X, Guo S, An Z, Chang JT, Liu QJ. Aberrant RSPO3-LGR4 signaling in Keap1-deficient lung adenocarcinomas promotes tumor aggressiveness. Oncogene. PMID 25531322 DOI: 10.1038/Onc.2014.417 |
0.333 |
|
2014 |
Li L, Liu C, Amato RJ, Chang JT, Du G, Li W. CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression. Oncotarget. 5: 10840-53. PMID 25333262 DOI: 10.18632/Oncotarget.2535 |
0.355 |
|
2014 |
Cheng Q, Chang JT, Gwin WR, Zhu J, Ambs S, Geradts J, Lyerly HK. A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype. Breast Cancer Research : Bcr. 16: 407. PMID 25060555 DOI: 10.1186/S13058-014-0407-9 |
0.324 |
|
2014 |
Zhao W, Tisza M, Sjol J, Mani S, Chang JT. Abstract 2080: Plasma membrane fluidity drives metastasis in breast cancer Cancer Research. 74: 2080-2080. DOI: 10.1158/1538-7445.Am2014-2080 |
0.349 |
|
2013 |
Lin SH, Beane L, Chasse D, Zhu KW, Mathey-Prevot B, Chang JT. Cross-platform prediction of gene expression signatures. Plos One. 8: e79228. PMID 24244455 DOI: 10.1371/Journal.Pone.0079228 |
0.308 |
|
2013 |
Tan TZ, Miow QH, Huang RY, Wong MK, Ye J, Lau JA, Wu MC, Bin Abdul Hadi LH, Soong R, Choolani M, Davidson B, Nesland JM, Wang LZ, Matsumura N, Mandai M, ... ... Chang JT, et al. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. Embo Molecular Medicine. 5: 983-98. PMID 23666744 DOI: 10.1002/Emmm.201201823 |
0.37 |
|
2013 |
Chang JT, Mani SA. Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition. Cancer Letters. 341: 16-23. PMID 23499890 DOI: 10.1016/J.Canlet.2013.03.004 |
0.322 |
|
2013 |
Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR, Sphyris N, Shariati M, Kumar SV, Battula VL, Herschkowitz JI, Guerra R, Chang JT, Miura N, Rosen JM, et al. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Research. 73: 1981-92. PMID 23378344 DOI: 10.1158/0008-5472.Can-12-2962 |
0.384 |
|
2013 |
Li L, Lu E, Chang J, Li W. Abstract A160: Characterization of novel regulators for epithelial-mesenchymal transition. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A160 |
0.353 |
|
2012 |
Cheng Q, Chang JT, Geradts J, Neckers LM, Haystead T, Spector NL, Lyerly HK. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Research : Bcr. 14: R62. PMID 22510516 DOI: 10.1186/Bcr3168 |
0.322 |
|
2012 |
Chang JT. Deriving transcriptional programs and functional processes from gene expression databases. Bioinformatics (Oxford, England). 28: 1122-9. PMID 22408194 DOI: 10.1093/Bioinformatics/Bts112 |
0.327 |
|
2011 |
Chang JT, Gatza ML, Lucas JE, Barry WT, Vaughn P, Nevins JR. SIGNATURE: a workbench for gene expression signature analysis. Bmc Bioinformatics. 12: 443. PMID 22078435 DOI: 10.1186/1471-2105-12-443 |
0.324 |
|
2011 |
Cohen AL, Soldi R, Zhang H, Gustafson AM, Wilcox R, Welm BE, Chang JT, Johnson E, Spira A, Jeffrey SS, Bild AH. A pharmacogenomic method for individualized prediction of drug sensitivity. Molecular Systems Biology. 7: 513. PMID 21772261 DOI: 10.1038/Msb.2011.47 |
0.353 |
|
2011 |
Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J, Nevins JR. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Research. 71: 1772-80. PMID 21169407 DOI: 10.1158/0008-5472.Can-10-1735 |
0.375 |
|
2009 |
Andrechek ER, Cardiff RD, Chang JT, Gatza ML, Acharya CR, Potti A, Nevins JR. Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proceedings of the National Academy of Sciences of the United States of America. 106: 16387-92. PMID 19805309 DOI: 10.1073/Pnas.0901250106 |
0.367 |
|
2009 |
Mori S, Chang JT, Andrechek ER, Potti A, Nevins JR. Utilization of genomic signatures to identify phenotype-specific drugs. Plos One. 4: e6772. PMID 19714244 DOI: 10.1371/Journal.Pone.0006772 |
0.367 |
|
2009 |
Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, Kim JW, Gatza M, Murphy S, Nevins JR. Anchorage-independent cell growth signature identifies tumors with metastatic potential Oncogene. 28: 2796-2805. PMID 19483725 DOI: 10.1038/Onc.2009.139 |
0.339 |
|
2009 |
Chang JT, Carvalho C, Mori S, Bild AH, Gatza ML, Wang Q, Lucas JE, Potti A, Febbo PG, West M, Nevins JR. A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Molecular Cell. 34: 104-14. PMID 19362539 DOI: 10.1016/J.Molcel.2009.02.030 |
0.301 |
|
2009 |
Matsumura N, Huang Z, Baba T, Lee PS, Barnett JC, Mori S, Chang JT, Kuo WL, Gusberg AH, Whitaker RS, Gray JW, Fujii S, Berchuck A, Murphy SK. Yin yang 1 modulates taxane response in epithelial ovarian cancer. Molecular Cancer Research : McR. 7: 210-20. PMID 19208743 DOI: 10.1158/1541-7786.Mcr-08-0255 |
0.374 |
|
2008 |
Carvalho CM, Chang J, Lucas JE, Nevins JR, Wang Q, West M. High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics. Journal of the American Statistical Association. 103: 1438-1456. PMID 21218139 DOI: 10.1198/016214508000000869 |
0.327 |
|
2007 |
Kong LJ, Chang JT, Bild AH, Nevins JR. Compensation and specificity of function within the E2F family. Oncogene. 26: 321-7. PMID 16909124 DOI: 10.1038/Sj.Onc.1209817 |
0.309 |
|
2007 |
Anguiano A, Mori S, Chang J, Vlahovic V, Kelley MJ, Ginsburg G, Dressman H, Nevins JR, Potti A. A genomic signature of chemotherapeutic multidrug resistance provides a rational approach to identify patients for targeted therapy in advanced solid tumors Journal of Clinical Oncology. 25: 10613-10613. DOI: 10.1200/Jco.2007.25.18_Suppl.10613 |
0.374 |
|
2006 |
Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Marks JR, Dressman HK, West M, Nevins JR. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 439: 353-7. PMID 16273092 DOI: 10.1038/Nature04296 |
0.364 |
|
2005 |
Delong M, Yao G, Wang Q, Dobra A, Black EP, Chang JT, Bild A, West M, Nevins JR, Dressman H. DIG--a system for gene annotation and functional discovery. Bioinformatics (Oxford, England). 21: 2957-9. PMID 15870167 DOI: 10.1093/Bioinformatics/Bti467 |
0.312 |
|
2005 |
Wren JD, Chang JT, Pustejovsky J, Adar E, Garner HR, Altman RB. Biomedical term mapping databases. Nucleic Acids Research. 33: D289-93. PMID 15608198 DOI: 10.1093/Nar/Gki137 |
0.429 |
|
2004 |
Chang JT, Altman RB. Extracting and characterizing gene-drug relationships from the literature. Pharmacogenetics. 14: 577-86. PMID 15475731 DOI: 10.1097/00008571-200409000-00002 |
0.452 |
|
2004 |
Chang JT, Schütze H, Altman RB. GAPSCORE: finding gene and protein names one word at a time. Bioinformatics (Oxford, England). 20: 216-25. PMID 14734313 DOI: 10.1093/Bioinformatics/Btg393 |
0.47 |
|
2003 |
Raychaudhuri S, Chang JT, Imam F, Altman RB. The computational analysis of scientific literature to define and recognize gene expression clusters. Nucleic Acids Research. 31: 4553-60. PMID 12888516 DOI: 10.1093/Nar/Gkg636 |
0.575 |
|
2002 |
Chang JT, Altman RB. Promises of text processing: natural language processing meets AI. Drug Discovery Today. 7: 992-3. PMID 12546913 DOI: 10.1016/S1359-6446(02)02457-1 |
0.392 |
|
2002 |
Chang JT, Schütze H, Altman RB. Creating an online dictionary of abbreviations from MEDLINE. Journal of the American Medical Informatics Association : Jamia. 9: 612-20. PMID 12386112 DOI: 10.1197/Jamia.M1139 |
0.431 |
|
2002 |
Raychaudhuri S, Chang JT, Sutphin PD, Altman RB. Associating genes with gene ontology codes using a maximum entropy analysis of biomedical literature. Genome Research. 12: 203-14. PMID 11779846 DOI: 10.1101/Gr.199701 |
0.574 |
|
2002 |
Chang J, Carrillo MW, Waugh A, Wei L, Altman RB. Scoring Functions Sensitive to Alignment Error Have a More Difficult Search: A Paradox for Threading Acs Symposium Series. 827: 309-320. |
0.691 |
|
2001 |
Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, Hewett M, Lin Z, Liu Y, Liu S, Oliver DE, Rubin DL, Shafa F, Stuart JM, Altman RB. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. The Pharmacogenomics Journal. 1: 167-70. PMID 11908751 DOI: 10.1038/Sj.Tpj.6500035 |
0.542 |
|
2001 |
Raychaudhuri S, Sutphin PD, Chang JT, Altman RB. Basic microarray analysis: grouping and feature reduction. Trends in Biotechnology. 19: 189-93. PMID 11301132 DOI: 10.1016/S0167-7799(01)01599-2 |
0.567 |
|
2001 |
Chang JT, Raychaudhuri S, Altman RB. Including biological literature improves homology search. Pacific Symposium On Biocomputing. Pacific Symposium On Biocomputing. 374-83. PMID 11262956 |
0.516 |
|
1998 |
Wei L, Chang J, Altman R. Chapter 11 Statistical analysis of protein structures: Using environmental features for multiple purposes New Comprehensive Biochemistry. 32: 207-225. DOI: 10.1016/S0167-7306(08)60468-8 |
0.426 |
|
1997 |
Wei L, Altman RB, Chang JT. Using the radial distributions of physical features to compare amino acid environments and align amino acid sequences. Pacific Symposium On Biocomputing. Pacific Symposium On Biocomputing. 465-76. PMID 9390315 |
0.331 |
|
Show low-probability matches. |